Andrada Mining acquisition elevates the miner to emerging mid-tier status. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAstrazeneca Regulatory News (AZN)

Share Price Information for Astrazeneca (AZN)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 12,356.00
Bid: 12,390.00
Ask: 12,394.00
Change: 28.00 (0.23%)
Spread: 4.00 (0.032%)
Open: 12,364.00
High: 12,454.00
Low: 12,322.00
Prev. Close: 12,328.00
AZN Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Form 8.3 - AstraZeneca PLC

21 May 2014 12:38

FORM 8.3

PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY

A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE

Rule 8.3 of the Takeover Code (the “Code”)

1. KEY INFORMATION
(a) Identity of the person whose positions/dealings are being disclosed: Wellington Management Company, LLP
(b) Owner or controller of interests and short positions disclosed, if different from 1(a):

The naming of nominee or vehicle companies is insufficient

(c) Name of offeror/offeree in relation to whose relevant securities this form relates:

Use a separate form for each offeror/offeree

AstraZeneca PLC
(d) If an exempt fund manager connected with an offeror/offeree, state this and specify identity of offeror/offeree:
(e) Date position held/dealing undertaken: 20 May 2014
(f) Has the discloser previously disclosed, or are they today disclosing, under the Code in respect of any other party to this offer? YES
2. POSITIONS OF THE PERSON MAKING THE DISCLOSURE
(a) Interests and short positions in the relevant securities of the offeror or offeree to which the disclosure relates following the dealing (if any)
Class of relevant security: Ordinary Shares (GB0009895292) and ADRs (US0463531089)
Interests Short Positions
Number % Number %
(1) Relevant securities owned and/or controlled: 64,500,768 shares 5.11 %
(2) Derivatives (other than options):
(3) Options and agreements to purchase/sell:
Total 64,500,768 shares 5.11 %
(b) Rights to subscribe for new securities (including directors’ and other executive options)
Class of relevant security in relation to which subscription right exists:
Details, including nature of the rights concerned and relevant percentages:
3. DEALINGS
(a) Purchases and sales
Class of relevant security Purchase/sale Number of securities Price per unit
Ordinary Shares (GB00098952922) Purchase 12,079 shares 42.8993 GBP
Ordinary Shares (GB00098952922) Sale 34,332 shares 43.0850 GBP
ADRs (US0463531089) Purchase 147,280 Depository Receipts (representing 147,280 shares on a converted basis) 71.8600 USD
(b) Derivatives transactions (other than options)
Class of relevant security Product description e.g. CFD Nature of dealing e.g. opening/closing a long/short position, increasing/reducing a long/short position Number of reference securities Price per unit
(c) Options transactions in respect of existing securities
(i) Writing, selling, purchasing or varying
Class of relevant security Product description e.g. call option Writing, purchasing, selling, varying etc. Number of securities to which option relates Exercise price per unit Type e.g. American, European etc. Expiry date Option money paid/ received per unit
(ii) Exercising
Class of relevant security Product description e.g. call option Number of securities Exercise price per unit
(d) Other dealings (including subscribing for new securities)
Class of relevant security Nature of dealing e.g. subscription, conversion Details Price per unit (if applicable)
4. OTHER INFORMATION
(a) Indemnity and other dealing arrangements
Details of any indemnity or option arrangement, or any agreement or understanding, formal or informal, relating to relevant securities which may be an inducement to deal or refrain from dealing entered into by the person making the disclosure and any party to the offer or any person acting in concert with a party to the offer:

If there are no such agreements, arrangements or understandings, state “none”

None
(b) Agreements, arrangements or understandings relating to options or derivatives
Details of any agreement, arrangement or understanding, formal or informal, between the person making the disclosure and any other person relating to:

(i) the voting rights of any relevant securities under any option; or

(ii) the voting rights or future acquisition or disposal of any relevant securities to which any derivative is referenced:

If there are no such agreements, arrangements or understandings, state “none”

None
(c) Attachments
Is a Supplemental Form 8 attached? NO
Date of disclosure 21 May 2014
Contact name John D. Norberg
Telephone number 617-790-7265

Public disclosures under Rule 8 of the Code must be made to a Regulatory Information Service and must also be emailed to the Takeover Panel at monitoring@disclosure.org.uk. The Panel’s Market Surveillance Unit is available for consultation in relation to the Code’s dealing disclosure requirements on +44 (0)20 7638 0129.

The Code can be viewed on the Panel?s website at www.thetakeoverpanel.org.uk.

Copyright Business Wire 2014

Date   Source Headline
5th Feb 20157:02 amRNSAZ to acquire Actavis' US respiratory portfolio
5th Feb 20157:00 amRNSFinal Results
4th Feb 20159:00 amRNSNotice of Results
2nd Feb 20152:00 pmRNSTotal Voting Rights
22nd Jan 20157:00 amRNSMAA FOR GOUT TREATMENT LESINURAD ACCEPTED BY EMA
14th Jan 20157:43 amRNSBRILINTA PEGASUS STUDY MEETS PRIMARY ENDPOINT
2nd Jan 20152:00 pmRNSTotal Voting Rights
19th Dec 20145:40 pmRNSLYNPARZA APPROVED BY THE US FDA
18th Dec 20147:00 amRNSLYNPARZAT APPROVED IN THE EUROPEAN UNION
9th Dec 20147:00 amRNSMOVENTIG approved in the EU for OIC
5th Dec 20145:03 pmRNSJury verdict favours AZ in Nexium litigation
2nd Dec 20147:00 amRNSNew Drug Application for IRESSA accepted by US FDA
1st Dec 20142:00 pmRNSBlocklisting Interim Review
1st Dec 20142:00 pmRNSTotal Voting Rights
26th Nov 20147:00 amRNSPOSITIVE RESULTS FROM BRODALUMAB PHASE III STUDY
24th Nov 20144:00 pmRNSPublication of Final Terms
24th Nov 20147:00 amRNSDUAKLIR GENUAIR APPROVED IN THE EU FOR COPD
19th Nov 20145:00 pmRNSLaunch and Pricing of a ?750m Bond
19th Nov 20149:41 amRNSStabilisation Notice
18th Nov 20147:00 amRNSAZ strategy on track to deliver growth and value
17th Nov 20144:00 pmRNSPublication of Supplementary Prospectus
12th Nov 20147:00 amRNSAMGEN & AZ POSITIVE PHASE III BRODALUMAB RESULTS
10th Nov 20142:27 pmRNSDirector/PDMR Shareholding
6th Nov 20147:04 amRNSASTRAZENECA TO DIVEST MYALEPT TO AEGERION
6th Nov 20147:00 amRNS3rd Quarter Results
6th Nov 20147:00 amRNS3rd Quarter Results
5th Nov 20147:00 amRNSNotice of Results
4th Nov 20147:00 amRNSMEDIMMUNE ACQUIRES DEFINIENS
3rd Nov 20143:00 pmRNSTotal Voting Rights
3rd Nov 20147:00 amRNSAZ COMPLETES STRATEGIC TRANSACTION WITH ALMIRALL
30th Oct 20147:00 amRNSUS FDA APPROVES ONCE-DAILY XIGDUOT XR TABLETS
24th Oct 201412:10 pmRNSOlaparib receives positive CHMP opinion
2nd Oct 20143:30 pmRNSDirector/PDMR Shareholding
1st Oct 20144:00 pmRNSTotal Voting Rights
29th Sep 20147:00 amRNSASTRAZENECA UPDATES ON ONCOLOGY PIPELINE AT ESMO
26th Sep 201411:15 amRNSPositive CHMP Opinion for MOVENTIG (naloxegol)
16th Sep 20144:27 pmRNSFDA Approves MOVANTIK (naloxegol) Tablets
16th Sep 20147:00 amRNSAZ AND LILLY ALLIANCE TO DEVELOP BACE INHIBITOR
10th Sep 20144:30 pmRNSDirector/PDMR Shareholding
1st Sep 20144:00 pmRNSTotal Voting Rights
19th Aug 20147:00 amRNSUS DOJ Closes Investigation into Plato
19th Aug 20147:00 amRNSCAZ-AVI PHASE III RESULTS
14th Aug 20147:00 amRNSTRALOKINUMAB PHASE III START IN SEVERE ASTHMA
13th Aug 20147:00 amRNSPHASE III RESULTS LESINURAD COMBINATION THERAPY
4th Aug 20141:00 pmRNSDirector/PDMR Shareholding
1st Aug 20142:00 pmRNSTotal Voting Rights
1st Aug 201411:30 amRNSDirector/PDMR Shareholding
31st Jul 20147:00 amRNSAstraZeneca Pipeline
31st Jul 20147:00 amRNSSecond Quarter & Half Year Results 2014
30th Jul 20149:00 amRNSNotice of Results

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.